Browse by category

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient

Pfizer and Metsera have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical...

ReShape has entered into an asset purchase agreement with Biorad Medisys, which is party to a previously disclosed exclusive license...

Asensus Surgical has entered into a definitive merger agreement with Karl Storz Endoscopy-America, a wholly owned direct subsidiary of...

Roche is poised to enter the lucrative anti-obesity medication market after entering into a definitive merger agreement to acquire Carmot...

Allurion Technologies and Compute Health Acquisition have entered into a definitive business combination agreement that will result in...

Teleflex has completed the previously announced acquisition of Standard Bariatrics, which has commercialised an innovative powered...

Teleflex it has entered into a definitive agreement to acquire Standard Bariatrics for an upfront cash payment of US$170 million at...

FitForMe, the global brand for bariatric supplements, has joined forces with Scandinavian-based, Baricol Bariatrics AB (Baricol), to...

Gryphon Investors, a leading private equity firm focused on profitably growing and competitively enhancing middle-market companies in...